TY - JOUR
T1 - A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia
AU - Cortelezzi, Agostino
AU - Pasquini, Maria Cristina
AU - Sarina, Barbara
AU - Bertani, Giambattista
AU - Grifoni, Federica
AU - Colombi, Mariangela
AU - Deliliers, Giorgio Lambertenghi
PY - 2005/3
Y1 - 2005/3
N2 - Subcutaneous low-dose alemtuzumab (10 mg t.i.w. for 18 weeks) induced a 50% response rate, including 25% complete response, in 16 patients with refractory chronic lymphocytic leukemia (CLL) patients. The responses were substantial even in patients with unfavorable cytogenetics, fludarabine/rituximab refractoriness, Rai stage IV, previous infections, and age over 65 years. Subcutaneous low-dose alemtuzumab is effective in poor prognosis B-CLL, and has a particularly favourable toxicity profile.
AB - Subcutaneous low-dose alemtuzumab (10 mg t.i.w. for 18 weeks) induced a 50% response rate, including 25% complete response, in 16 patients with refractory chronic lymphocytic leukemia (CLL) patients. The responses were substantial even in patients with unfavorable cytogenetics, fludarabine/rituximab refractoriness, Rai stage IV, previous infections, and age over 65 years. Subcutaneous low-dose alemtuzumab is effective in poor prognosis B-CLL, and has a particularly favourable toxicity profile.
KW - Alemtuzumab
KW - Autoimmune hemolytic anemia
KW - B-CLL
KW - Complete response
KW - HBV
KW - Overall response
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=15244362778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15244362778&partnerID=8YFLogxK
M3 - Article
C2 - 15749678
AN - SCOPUS:15244362778
VL - 90
SP - 410
EP - 412
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 3
ER -